The Drug Design Group conducts research in the field of Computational Drug Discovery, aiming to accelerate the development of new medicines and leveraging its strengths to identify novel inhibitors for various diseases, including tuberculosis, coronavirus, and cancer.
Our focus is on the early stages of structure-based drug discovery, from virtual screening to experimental validation of hits, prior to lead optimization. We integrate our proficiency in using a structure-based in silico drug discovery toolkit and applying AI for drug identification with extensive experience in computational workflow automation, contributing to the advancement of the field and the identification of novel hits.
